ACR
<ѻý class="page-description">American College of Rheumatologyѻý>Mechanism different from currently available therapies
Worries about vaccine responsiveness relieved; Big Pharma gets interested
Computer matches live expert in measuring joint space and erosions
More phase II data build case for izokibep
Something to consider when prescribing SGLT-2 inhibitors
Phase II results pave way for bigger and better trial
Placebo-controlled trial gives novel product a tentative boost
AI will revolutionize how healthcare is delivered; how is yet to be determined
Study should help target frequent testing to those most likely to benefit
Secondary trial analysis boosts case for Gazyva
Provocative findings with denosumab, but don't reach for the prescription pad just yet
Novel approach to normalizing immune activity
Small study suggests at least a 10-day holiday
Trial data pave way for FDA approval
-
ACR: American College of Rheumatology
November 2024
-
EULAR: European Alliance of Associations for Rheumatology
June 2024
-
BSR: British Society for Rheumatology
April 2020
-
ACR-SOTA: ACR State-of-the-Art Clinical Symposium
March 2020